๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University451 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181 Nanfang Hospital, Southern Medical University138 AstraZeneca133 Guangdong Provincial People's Hospital81
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Guangzhou

3318 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Efficacy and Safety of a Third-Course of Neoadjuvant Immunochemotherapy Combined With SBRT in Locally Advanced Head and Neck Squamous Cell Carcinoma Patients With Stable Disease After Two Treatment Courses: A Single-Arm Exploratory Study
NCT06722495SBRT, Neoadjuvant Immunochemotherapy, LA HNSCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
20
Guangzhou
2024-12-24
Recruiting
A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia
NCT07251309Hyperkalemia
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Phase 3
420
Bengbu, Wuhu, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhanjiang, Huizhou
2024-12-23
Recruiting
Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
NCT06735144Malignant Solid Tumor
DrugFH-006
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
200
Guangzhou
2024-12-23
Recruiting
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
NCT07016126NSCLC (Non-small Cell Lung Cancer)
Guangdong Provincial People's Hospital
Phase 3
70
Guangzhou
2024-12-22
Recruiting
The Optimal Radioimmunotherapy Combinations for Advanced TNBC
NCT06735131Triple-Negative Breast Cancer (TNBC)
Sun Yat-sen University
Phase 2
60
Guangzhou
2024-12-20
Active, closed
Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors
NCT06806046Solid Tumors, Colorectal Cancer
DrugM9140
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1
12
Beijing, Guangzhou, Hangzhou
2024-12-20
Recruiting
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
NCT06754085Prostate Cancer
HTA Co., Ltd.
Phase 3
131
Guangzhou
2024-12-19
Recruiting
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction
Cytokinetics
Phase 3
1,800
Beijing, Lanzhou, Guangzhou, Shenzhen, Nanning, Luoyang, Changsha, Chifeng
2024-12-19
Recruiting
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
DrugsICP-248·Azacitidine
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
266
Hefei, Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-12-18
Recruiting
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
NCT06687070Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor
DrugsAPG -2449·PLD
Ascentage Pharma Group Inc.
Phase 1
90
Guangzhou
2024-12-17
Recruiting
Validation of the Accuracy of a Novel POCT Dry Electrolyte Analysis System in the Acute Care Setting
NCT06726460Electrolyte Disorder, Arrhythmia, Stroke
Zhujiang Hospital
Observational
200
Guangzhou
2024-12-17
Active, closed
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)
NCT06612151Small Cell Lung Cancer
DrugsTopotecan hydrochloride·Tam-Peli
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
438
Guangzhou
2024-12-17
Recruiting
A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors
NCT06725381Solid Malignancies
DrugSKB571
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
138
Guangzhou, Nanning, Wuhan, Changsha, Nanjing, Jinan, Linyi, Chengdu
2024-12-17
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai
2024-12-16
Recruiting
Intrathecal Morphine for Postoperative Analgesia in Major Laparoscopic Abdominal Surgery, a IMPACT-Scope Trial
NCT06666985Patients Undergoing Major Laparoscopic Abdominal Surgery
First Affiliated Hospital, Sun Yat-Sen University
Phase 4
700
Guangzhou
2024-12-16
Recruiting
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
NCT06439342Cytomegalovirus (CMV)
DrugMaribavir
Takeda
Phase 3
20
Hefei, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Beijing, Tianjin
2024-12-16
By invitation
Non-invasive Methods for Predicting Decompensation of Chronic Liver Disease
NCT06741904Chronic Liver Disease and Cirrhosis
Nanfang Hospital, Southern Medical University
Observational
2,334
Guangzhou
2024-12-16
Recruiting
Using Mukbang to Improve Appetite, Nutritional Status and Quality of Life in Children With Cancer
NCT05922553Children With Cancer
Wei XIA, PhD
Not applicable
124
Guangzhou
2024-12-16
Not yet open
Construction of a Risk Screening Tool for New Psychoactive Substance Misuse Among Adolescents and Young Adults
NCT06714578Drug Misuse, Addiction
Wei XIA, PhD
Observational
1,035
Guangzhou
2024-12-15
Active, closed
Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma ๏ผˆHNC-SYSU-005๏ผ‰
NCT07267286HNSCC, PD-1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
60
Guangzhou
2024-12-15
Recruiting
Efficacy and Influencing Factors of ALIC-NAc Deep Brain Stimulation in Treatment-Refractory Obsessive-Compulsive Disorder
NCT07031544Obsessive - Compulsive Disorder
Shanghai Mental Health Center
Not applicable
60
Guangzhou, Shijiazhuang, Xinxiang, Nanchang, Taiyuan, Mianyang, Shanghai, Tianjin
2024-12-14
Active, closed
Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)
NCT06829329Chronic Hepatitis B
DrugsNAs·AHB-137
Ausper Biopharma Co., Ltd.
Phase 2
105
Chongqing, Fuzhou, Guangzhou, Changzhou, Zhenjiang, Hangzhou
2024-12-13
Recruiting
Normobaric Oxygen in AIS Transferred for EVT
NCT06666764Ischemic Stroke
Capital Medical University
Phase 3
1,500
Beijing, Fuzhou, Ningde, Putian, Zhangzhou, Guangzhou, Hezhou, Cangzhou
2024-12-13
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Irinotecan·Pemetrexed
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Changsha, Chengdu, Ganzhou, Guangzhou, Hangzhou, Harbin
2024-12-12
Recruiting
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
NCT06584032Advanced Endometrial Cancer
DrugsFruquintinib·Doxorubicin·Sintilimab·Paclitaxel
Hutchmed
Phase 3
412
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha
2024-12-12
Recruiting
TEOSYAL RHAยฎ 1 for the Correction of Moderate to Severe Tissue Volume Deficiency in the Infraorbital Region in Chinese Adults
NCT06749587Infraorbital Hollows
Teoxane SA
Not applicable
260
Guangzhou
2024-12-12
Recruiting
A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
NCT06686576Colon Cancer
DrugIparomlimab and Tuvonralimab
Qilu Pharmaceutical Co., Ltd.
Phase 3
363
Guangzhou
2024-12-12
Recruiting
Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
NCT06836505Neuroblastoma (NB), Desmoplastic Small Round Cell Tumor (DSRCT)
Sun Yat-Sen University Cancer Center
Phase 1/2
10
Guangzhou, Dongguan, Shanghai
2024-12-12
Recruiting
Inhaled Nitric Oxide for the Treatment of Neonatal Hypoxic Respiratory Failure With Pulmonary Hypertension
NCT07099144Pulmonary Hypertension, Hypoxic Respiratory Failure
DrugNitric Oxide
Lee's Pharmaceutical Limited
Observational
120
Guangzhou
2024-12-12
Recruiting
The Safety and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Metastatic Adenocarcinoma
NCT06743867Peritoneal Carcinoma Metastatic
Guangdong Provincial People's Hospital
Phase 1
30
Guangzhou
2024-12-11
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858Candidemia, Candidiasis, Invasive
DrugsCaspofungin·Fosmanogepix·Fluconazole
Basilea Pharmaceutica
Phase 3
450
Beijing, Bengbu, Chengdu, Guangzhou, Hangzhou, Lishui, Liuzhou, Nanchang
2024-12-11
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
350
Beijing, Kunming, Changsha, Chengdu, Guangzhou, Hangzhou, Huizhou, Nanchang
2024-12-11
Active, closed
Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer
NCT07046195Hypofractionated Radiotherapy, Triple Negative Breast Cancer (TNBC), Immunotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
250
Guangzhou
2024-12-11
Recruiting
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung Cancer
NCT06730295Lung Cancer (NSCLC)
Sun Yat-sen University
Phase 2
52
Guangzhou
2024-12-10
Active, closed
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
NCT06637631Crohn's Disease
DrugSAR441566
Sanofi
Phase 2
260
Changzhou, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Nanchang, Shanghai
2024-12-10
Recruiting
Clinical Trial of TQB3002 in Patients With Advanced Cancers
NCT06662760Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
150
Guangzhou, Shenzhen, Zhengzhou, Nanjing, Nanchang, Shanghai, Xiโ€™an, Chengdu
2024-12-09
By invitation
Evaluating App-Based Vision Testing (WHOeyes) Combined With the Questionnaire as a Substitute for One-Week Postoperative In-Clinic Follow-Up in Age-Related Cataract Patients: A Multi-center Randomized Controlled Trial
NCT06429527Cataract Senile
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
334
Guangzhou
2024-12-09
Recruiting
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
NCT06679140COVID-19 SARS-CoV-2 Infection
DrugIbuzatrelvir
Pfizer
Phase 3
2,330
Chizhou, Beijing, Xiamen, Guangzhou, Nanning, Changsha, Nanchang, Changchun
2024-12-08
Recruiting
Long-term Follow-up Study of BRL-101 for TDT
NCT06298630Thalassemia, Beta
Bioray Laboratories
Observational
45
Guangzhou, Shenzhen, Nanning, Changsha, Tianjin, Guangxi
2024-12-08
Recruiting
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
NCT06667908Carcinoma, Non-Small-Cell Lung
DrugsJNJ-90301900·Durvalumab
Johnson & Johnson Enterprise Innovation Inc.
Phase 2
130
Dongguan, Guangzhou, Jinan
2024-12-06
Recruiting
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
NCT06497985Colorectal Cancer
DrugsTucidinostat·Fruquintinib·Sintilimab·Bevacizumab
Chipscreen Biosciences, Ltd.
Phase 3
430
Guangzhou
2024-12-06
Recruiting
Breathomics in the Diagnosis and Prediction of Radiotherapy-Induced Oropharyngeal Mucositis in Head and Neck Tumors
NCT06767488Head and Neck Tumors, Breathomics, Volatile Organic Compounds, Radiotherapy-induced Oral Mucositis
Nanfang Hospital, Southern Medical University
Observational
375
Guangzhou
2024-12-06
Active, closed
Effects of DL-endopeptidase Producing Probiotics on Human Intestinal NOD2 Ligands and Related Functions
NCT06716047Microecological Therapy, Probiotic Intervention
Zhujiang Hospital
Phase EARLY_PHASE1
30
Guangzhou
2024-12-05
Recruiting
nVNS for the Prevention and Treatment of Primary Headache
NCT06277063Primary Headache, Migraine in Adolescence, Migraine in Children, Cluster Headache
Nanfang Hospital, Southern Medical University
Not applicable
15
Guangzhou
2024-12-05
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
655
Beijing, Changsha, Changzhou, Chengdu, Dazhou, Ganzhou, Guangzhou, Guiyang
2024-12-04
Active, closed
Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection
NCT06706310Chronic Hepatitis B
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
116
Chongqing, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha, Wuxi, Changchun
2024-12-04
Recruiting
Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim in Pediatric Cancer Patients with Chemotherapy
NCT06857292Chemotherapy-Induced Neutropenia
DrugTelpegfilgrastim
Sun Yat-sen University
Phase 2
97
Guangzhou
2024-12-01
Recruiting
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
NCT06497530Extensive-Stage Small Cell Lung Cancer
DrugsLurbinectedin·Serplulimab·Etoposide·Carboplatin
Guangzhou Institute of Respiratory Disease
Phase 2
30
Guangzhou
2024-12-01
Active, closed
Cognitive Function and EEG Brain Network Remodeling Among Users of Hearing Aids With ARHL
NCT06893432Age-related Hearing Loss, Age-related Cognitive Decline, Depression, Sleep Disturbance
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
60
Guangzhou
2024-12-01
Recruiting
Y-90 SIRT for Unresectable HCC Larger Than 7cm
NCT06707233Hepatocellular Carcinoma Non-Resectable
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
33
Guangzhou
2024-12-01
Not yet open
A Prospective, Non-interventional Cohort Study of Subsolid Pulmonary Nodules
NCT06458673Solitary Lung Nodule, Multiple Pulmonary Nodules
Guangdong Provincial People's Hospital
Observational
1,184
Guangzhou
2024-12-01
Recruiting
Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study
NCT06728852Advanced Non-small Cell Lung Cancer (NSCLC), Recurrent or Metastatic Lung Cancer, Third-line and Beyond Therapy, Angiogenesis Inhibition in Oncology
Li-kun Chen
Phase 2
32
Guangzhou
2024-12-01
Recruiting
ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
NCT06426511Lung Cancer, Nonsmall Cell
Sun Yat-sen University
Phase 2
80
Guangzhou
2024-12-01
Recruiting
To Assess the Effectiveness and Safety of Catheter-based Focal Intracranial Hypothermia Combined with Endovascular Reperfusion Therapy for Patients with Acute Anterior Circulation Large Artery Occlusion
NCT06758609Acute Cerebrovascular Accident, Acute Ischemic Stroke, Internal Carotid Artery, Middle Cerebral Artery Occlusion
Guangdong Second Provincial General Hospital
Not applicable
262
Guangzhou
2024-12-01
Not yet open
Observational Study of Sputum Inflammation Phenotypes and Clinical Outcomes in Non-Cystic Fibrosis Bronchiectasis
NCT06715956Non-cystic Fibrosis Bronchiectasis (NCFBE)
Guangzhou Institute of Respiratory Disease
Observational
400
Guangzhou
2024-12-01
Recruiting
Efficacy and Safety of Additive Manufacturing Personalized Titanium Mesh in Guided Bone Regeneration
NCT06692244Alveolar Bone Atrophy, Guided Bone Regeneration
Hospital of Stomatology, Sun Yat-Sen University
Not applicable
142
Guangzhou
2024-11-30
Recruiting
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
NCT06734702Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy, Locally Advanced Non-Small Cell Lung Cancer
Sun Yat-sen University
Phase 3
497
Guangzhou
2024-11-30
Recruiting
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
NCT06719700Toripalimab, Surufatinib, Chemoradiotherapy, Limited-stage Small Cell Lung Cancer (LS-SCLC)
Sun Yat-sen University
Phase 2
47
Guangzhou
2024-11-30
Active, closed
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC
NCT06671379Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
498
Guangzhou
2024-11-29
Recruiting
Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
NCT06644937Hepatocellular Carcinoma (HCC)
Zhujiang Hospital
Phase 2/3
30
Guangzhou
2024-11-29
Active, closed
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
NCT06666855Open Angle Glaucoma, Ocular Hypertension
Santen Pharmaceutical Co., Ltd.
Phase 3
345
Beijing, Guangzhou, Guiyang, Hangzhou, Heilongjiang, Jinan, Lanzhou, Luoyang
2024-11-28
Recruiting
A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes
NCT06712680Solid Tumor
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2
115
Guangzhou
2024-11-27
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Chengdu, Guangzhou, Nanchang, Nanjing, Nantong, Shandong, Shanghai, Tianjin
2024-11-27
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
DrugsRilvegostomig·Pemetrexed·Cisplatin·Carboplatin
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-11-27
Active, closed
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06670196Non-Small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Osimertinib
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
420
Guangzhou
2024-11-27
Recruiting
Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT06669611Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
242
Guangzhou
2024-11-27
Recruiting
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
NCT06564324Non Small Cell Lung Cancer
DrugsTaletrectinib·Crizotinib
Nuvation Bio Inc.
Phase 3
194
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Zhengzhou
2024-11-27
Recruiting
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06634589B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
DrugsTacabrutideg·Mosunetuzumab·Sonrotoclax·Glofitamab
BeOne Medicines
Phase 1/2
80
Fuzhou, Guangzhou, Suzhou, Hangzhou, Wenzhou
2024-11-27
Not yet open
Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia
NCT06702098Acute Myeloid Leukemia (AML)
Guangzhou Ruixin Biotechnological Co., LTD
Phase EARLY_PHASE1
10
Guangzhou
2024-11-25
Not yet open
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
NCT06662877Biliary Tract Cancer, Second Line Treatment, Chemotherapy, Tyrosine Kinase Inhibitor
DrugsFolfox·Albumin-Bound Paclitaxel·Tegafur Gimeracil Oteracil·Anlotinib
Sun Yat-sen University
Phase 2/3
206
Guangzhou
2024-11-25
Recruiting
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
NCT06959615Advanced Solid Tumor
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
334
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Langfang, Haerbin, Zhengzhou
2024-11-22
Recruiting
SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06649292Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 3
524
Guangzhou
2024-11-22
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
450
Baotou, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Guangzhou
2024-11-21
Active, closed
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042Lung Cancer, Non-Small Cell Lung Cancer
Drugs) Berahyaluronidase alfa·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
67
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Huizhou, Jiangmen, Liuzhou
2024-11-21
Recruiting
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
NCT06682169Graft-versus-host Disease
DrugsRovadicitinib·Mycophenolate Mofetil·Imatinib·Methotrexate
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
182
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2024-11-20
Recruiting
Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma
NCT07602049Soft Tissue Sarcoma (STS), Osteosarcoma
Sun Yat-sen University
Phase 2
57
Guangzhou
2024-11-20
Recruiting
A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)
NCT06829147Nasopharyngeal Cancinoma (NPC), Lymph Node Metastasis
Sun Yat-sen University
Observational
500
Guangzhou
2024-11-19
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
DrugQuizartinib
Daiichi Sankyo
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Jinan, Nanchang, Nanjing
2024-11-19
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
DrugsRilvegostomig·Nab-paclitaxel·Carboplatin·Pembrolizumab
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian, Guangzhou
2024-11-18
Recruiting
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
NCT06568471Hypercholesterolemia, Dyslipidemias, Primary Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
DrugLerodalcibep
Hasten Biopharmaceutical Co., Ltd.
Phase 3
210
Beijing, Guangzhou, Shijiazhuang, Daqing, Changsha, Nanchang, Binzhou, Heze
2024-11-16
Recruiting
Tissue-resident Immune Cell Subsets in aGVHD
NCT06708507Acute Graft-versus-Host Disease, Hematopoietic Stem Cell Transplantation
Nanfang Hospital, Southern Medical University
Observational
40
Guangzhou
2024-11-16
Recruiting
Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab
NCT06652113Recurrent Pregnancy Loss, Euthyroid With Thyroid Antibodies
DrugLevothyroxine
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
796
Guangzhou
2024-11-15
Recruiting
A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy
NCT06654440Advanced Gynecological Malignancy
DrugSHR-A2102
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2
100
Guangzhou
2024-11-15
Active, closed
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194Migraine
DrugRimegepant
Pfizer
Phase 3
200
Beijing, Chongqing, Guangzhou, Jingzhou, Wuhan, Changsha, Suzhou, Wuxi
2024-11-15
Active, closed
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
NCT06680921Locally Advanced or Metastatic Breast Cancer
DrugsSIM0270·Exemestane·Everolimus·Fulvestrant
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
482
Bengbu, Hefei, Maanshan, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou
2024-11-14
Recruiting
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
NCT06775860Atopic Dermatitis
DrugICP-332
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
552
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shaoguan
2024-11-14
Not yet open
Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC
NCT06699459Biliary Tract Carcinoma
DrugsIrinotecan liposome·Capecitabine
Sir Run Run Shaw Hospital
Phase 2
76
Fuzhou, Guangzhou, Shanghai, Hangzhou
2024-11-14
Recruiting
Safety and Effectiveness of Early Aspirin Administration After Mitral Valve Repair
NCT06738992Mitral Valve Repair Surgery
Guangdong Provincial People's Hospital
Phase 4
384
Guangzhou
2024-11-14
Active, closed
An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients
NCT06605885Asthma
AstraZeneca
Observational
202
Hohhot, Beijing, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou
2024-11-14
Recruiting
Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL
NCT06985472Initial MZL, Untreated MZL, BTKi, CD20
Li Zhiming
Phase 2
33
Guangzhou
2024-11-13
Active, closed
A Real-world Study to Assess Safety of OZURDEXยฎ (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China
NCT06548568Diabetic Macular Edema
AbbVie
Observational
110
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Dalian, Xi'an, Qingdao
2024-11-13
By invitation
Multicenter Prospective Cohort Study of Hypertriglyceridemia Acute Pancreatitis
NCT06976099Acute Pancreatitis (AP), Hypertriglyceridemia Acute Pancreatitis
Peking Union Medical College Hospital
Observational
1,000
Beijing, Guangzhou, Zunyi, Harbin, Changsha, Nanjing, Yangzhou, Dalian
2024-11-13
Recruiting
Evaluating the Safety and Effectiveness of 5G Cloud Follow-up for Cardiovascular Implantable Electronic Devices
NCT06652750Sick Sinus Syndrome, Atrioventricular Block, Second and Third Degree, Heart Failure
The Third People's Hospital of Chengdu
Not applicable
688
Guangzhou, Chengdu
2024-11-13
Recruiting
Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia
NCT06624696Respiratory Hypersensitivity, Perioperative Respiratory Adverse Events, Anticholinergics, Inhalation Therapy; Complications
Sun Yat-sen University
Phase 4
204
Guangzhou, Shenzhen
2024-11-12
Recruiting
Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
NCT06742502Primary Mediastinal Diffuse Large B-cell Lymphoma
Sun Yat-sen University
Phase 2
30
Fuzhou, Guangzhou
2024-11-12
Active, closed
A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
NCT06297655Hemophilia A
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
60
Fuyang, Hefei, Chongqing, Lanzhou, Guangzhou, Nanning, Zhengzhou, Changsha
2024-11-12
Active, closed
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B
DrugBepirovirsen
GlaxoSmithKline
Phase 2
283
Beijing, Chengdu, Guangzhou, Shanghai
2024-11-11
Active, closed
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141Developmental and Epileptic Encephalopathy
DrugLP352
Longboard Pharmaceuticals
Phase 3
367
Beijing, Guangzhou, Shenzhen Shi, Wuhan, Shanghai Shi
2024-11-11
Recruiting
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
NCT06647862Chronic Myelomonocytic Leukemia
DrugAzacitidine
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 3
170
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Guangzhou, Shenzhen, Zhujiang
2024-11-11
Recruiting
A Real World Study About PMN
NCT06893328Primary Membranous Nephropathy
Wei Chen
Observational
200
Guangzhou
2024-11-11
Rows per page Showing 1501–1600 of 3318
Previous 14 15 16 17 18 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=16

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,318 of those studies with a site in Guangzhou.

How many clinical trials are recruiting in Guangzhou?

1,972 of the 3,318 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 473 have not yet opened recruitment, 805 are active but closed to new participants, and 68 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.